![Restoration of Li+ pathways in the [010] direction during direct regeneration for spent LiFePO4](http://pubs.rsc.org/services/images/RSCpubs.ePlatform.Service.FreeContent.ImageService.svc/ImageService/image/GA?id=D5EE00641D)
.jpg)
Prime sets sights on liver, lung disease as next target for its gene editing tech
The biotech unveiled a new research program in alpha-1 antitrypsin deficiency, a disease that’s also a focus for rival Beam Therapeutics.
The biotech unveiled a new research program in alpha-1 antitrypsin deficiency, a disease that’s also a focus for rival Beam Therapeutics.
